Abstract
Background
In patients with hypertriglyceridemia, non‐high density lipoprotein cholesterol (nonHDL‐C) is a targeted goal. However, apoprotein B100 (apoB) may be superior in predicting cardiovascular risk so we assessed the utility of an apoB‐based.
Methods
New patients (n = 125) who had both apoB and standard lipids measured on the same day were included and we determined the concordances of having achieved goal lipid levels based upon proposed apoB versus nonHDL‐C (ATP III) targets in patients with elevated TG (≥150 mg·dl−1) levels.
Results
Although apoB was correlated with nonHDL‐C (r = 0.47, p ≤ 0.001), the tests had only a fair level of agreement when categorizing the percentage of patients achieving lipid goals for their degree of cardiovascular risk (κ = 0.22). Among patients with an elevation in nonHDL‐C above ATP III goals, between 12–42% had achieved target apoB. On the contrary, between 44–50% of patients were found to be at nonHDL‐C but not apoB target. The results were not substantively altered if the analyses were confined to patients with TG values between 200–499 mg·dl−1, rather than all patients with TG levels ≥ 150 mg·dl−1, as specifically outlined in ATP III guidelines. In total, > 50% of all subjects would have been treated either more or less aggressively following an apoB‐based therapeutic algorithm.
Conclusions
Our findings confirm that the majority of patients referred with hypertriglyceridemia would be managed differently by following an apoB‐based treatment algorithm compared to ATP III guidelines. Although many patients would be candidates for more intense therapy, many would be treated less aggressively. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (98.9 KB).
References
- 1. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B veresus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty‐person/ten‐country panel. J Intern Med 2006; 259: 247–258. [DOI] [PubMed] [Google Scholar]
- 2. Sniderman AD, Furberg CD, Keech A, et al. Apolipoporteins verus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777–780. [DOI] [PubMed] [Google Scholar]
- 3. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447–459. [DOI] [PubMed] [Google Scholar]
- 4.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2509. [DOI] [PubMed] [Google Scholar]
- 5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239. [DOI] [PubMed] [Google Scholar]
- 6. St‐Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B. Apolipoprtein‐B, low‐density lipoprotein cholesterol, and the long‐term risk of coronary heart disease in men. Am J Cardiol 2006; 97: 997–1001. [DOI] [PubMed] [Google Scholar]
- 7. Sniderman AD, St‐Pierre AC, Cantin B, et al. Concordance/ discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173–1177. [DOI] [PubMed] [Google Scholar]
- 8. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: Low‐density lipoprotein cholesterol, non‐high‐density lipoprotein cholesterol, or apoliprotein B. Am J Cardiol 2005; 96(9a): 36K–43K. [DOI] [PubMed] [Google Scholar]
- 9. Pischon T, Girman CJ, Sacks FM, et al. Non‐high‐density lipoprotein cholesterol and apoliprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375–3383. [DOI] [PubMed] [Google Scholar]
- 10. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA‐I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and anitatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355–1363. [DOI] [PubMed] [Google Scholar]
- 11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359. [DOI] [PubMed] [Google Scholar]
- 12. Genest J, Frohlich J, Fodor G, McPherson R. Working Group on Hypercholesterolemia and Other Dyslipidemias: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. Can Med Assoc J 2003; 169: 921–924. [PMC free article] [PubMed] [Google Scholar]